U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06904573) titled 'Probiotics in Advanced Urothelial Carcinoma' on March 15.
Brief Summary: This is a multicenter, randomized, controlled phase II Study of evaluating the efficacy and safety of immunotherapy combined with probiotics compound (Biolosion) in patients with advanced urothelial carcinoma.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Advanced Urothelial Carcinoma
Probiotics
Immunotherapy
Intervention:
DRUG: Probiotics Compound (Biolosion)
15g, PO, qd
DRUG: Nab-paclitaxel
230mg/m2, IV, days 1, 8, q3w
DRUG: Cisplatin
70mg/m2, IV, days 1-3, q3w
DRUG: Gemcitabine
1.2g/m2, IV, days 1, 8, q3w
DRUG: Disitamab vedot...